Lupus Research Alliance News
A Message from LRA President Introducing LRA’s celebration of Lupus Awareness Month

Dear Friends, Lupus Awareness Month officially starts today, and with so many advancements, never has there been a time for more optimism. We are delighted to begin May following a productive first-anniversary meeting of the Lupus Accelerating Breakthroughs Consortium (Lupus ABC) where people with lupus partner with representatives from the FDA, industry, and researchers on […] READ MORE

Expert Global Task Force Issues Recommendations for Physical Activity and Exercise in People with SLE

April 15, 2024 An international task force recently published their recommendations for physical activity and exercise in people with systemic lupus erythematosus (SLE). While the benefit of physical activity in lupus is already recognized, no recommendations had been previously established. Published in the peer-reviewed journal Rheumatic & Musculoskeletal Diseases, this study outlines specific recommendations for […] READ MORE

Lupus Accelerating Breakthroughs Consortium Announces Expanded Partnership with U.S. FDA at First Anniversary Meeting

BETHESDA, MD – [April 16] The Lupus Research Alliance (LRA), founder and administrator of the Lupus Accelerating Breakthroughs Consortium (Lupus ABC), announced today at the Consortium’s first anniversary meeting an expanded partnership with the U.S. Food and Drug Administration (FDA) with the inclusion of the Center for Biologics Evaluation and Research (CBER). The addition of […] READ MORE

LRA Announces Partners on the First Anniversary of the Lupus Landmark Study

April 11, 2024 The Lupus Research Alliance (LRA) and its clinical research affiliate Lupus Therapeutics (LT) are pleased to announce the group of industry partners working together on the implementation of the Lupus Nexus. The Lupus Nexus, one of LRA’s most ambitious and groundbreaking endeavors, is a first-of-its-kind lupus registry, biorepository, and data exchange platform […] READ MORE

Meet Unstoppable Advocate for Minority Health Christopher Reed

April 2, 2024 Determined to alleviate healthcare disparities for minorities, J. Christopher Reed, JD, urges our lupus community to use the power of National Minority Health Month to spotlight the issue this April. First diagnosed at 16, Christopher fought debilitating lupus symptoms to graduate college in eight years and then Tulane University Law School in […] READ MORE

Lupus Peer-to-Peer Early Education Program Expands

March 28, 2024 Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, has announced an innovative expansion of the highly successful Patient Advocates for Lupus Studies (PALS) program with the introduction of a first-in-lupus “Trial Buddy” component made possible by a partnership with Bristol Myers Squibb. The Trial Buddy addition provides extra support […] READ MORE

Congress Passes Budget With $10M for Lupus Research Program

March 24, 2024 Congress and passed and President Biden signed the 2024 spending bills, which include priorities that you, our advocates requested last March.  The Defense Appropriations bill includes $10 million for the Lupus Research Program within the Department of Defense.  And the Agriculture-FDA bill includes a provision expressing support for FDA’s engagement with industry […] READ MORE

Recent Discoveries Shedding Light on Why Women Are at a Greater Risk for Lupus

March 20, 2024 Lupus is a complex autoimmune disease affecting millions worldwide with a staggering gender imbalance — about 9 of 10 people with lupus are women. Underlying biological, hormonal, or environmental factors likely contribute to why lupus affects females more often. Understanding why women are at greater risk for lupus could unlock novel treatments […] READ MORE

Lupus Therapeutics Announces Collaboration to Support the Evaluation of Non-Genetically Modified Cell-Based Therapy for Lupus Nephritis with Artiva Biotherapeutics

NEW YORK, N.Y. — [March 14, 2024]: Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, announced a collaboration with Artiva Biotherapeutics, Inc. on a Phase 1 trial of the company novel NK cell-based therapy AlloNK® (also known as AB-101), in combination with anti-CD20 antibodies, for patients with active lupus nephritis – inflammation […] READ MORE

Together, ManyOne Can make a difference!
Stay informed about events, research developments, and ways you can help. Sign up for updates